On November 3 this year, Luye Pharmaceutical announced that its self-developed class 1 innovative drug toludi venlafaxine hydrochloride sustained-release tablets (trade name: Ruoxinlin) was officially approved by the National Medical Products Administration for the treatment of depression
.
One month later, Luye Pharmaceutical announced that it signed a tripartite strategic cooperation agreement
with Enhua Pharmaceutical, Good Mood Health Industry Group and its subsidiary Beijing Good Mood Internet Hospital Co.
, Ltd.
According to the data, Ruoxinlin is the first class 1 innovative drug independently developed and has independent intellectual property rights for the treatment of depression in China, and the listing of this variety is a major breakthrough
in the field of treatment of domestic innovative drugs.
Preclinical studies have shown that the drug has a reuptake inhibitory effect
on the monoamine neurotransmitters serotonin (5-HT), norepinephrine (NE), and dopamine (DA).
Clinical studies have shown that Ruoxinlin has a stable antidepressant effect, has good safety and tolerability, does not cause drowsiness, and does not affect sexual function, body weight and lipid metabolism
.
In addition, phase III clinical trials for its use in the treatment of generalized anxiety disorder are also ongoing
.
Luye Pharmaceutical is committed to the research and development, production and sales of innovative drugs, including depression and other central nervous system treatment is one of the company's core strategic areas, around this disease field, the company has been actively building innovative product portfolios, improving self-operated teams, sinking channels and expanding the market for many years, and has now promoted central nervous system products to cover nearly 3,000 hospitals in China, and the commercialization advantage is increasingly prominent
.
Enhua Pharmaceutical also has a presence in the domestic central nervous system field, focusing on the development
of innovative and differentiated product pipelines in the fields of anesthesia, analgesia, psychiatry and neurology.
In recent years, the company has further strengthened its market position
by providing accurate diagnosis services for central nervous system diseases (Shanghai Enyuan) and establishing one of China's largest central nervous system Internet health platforms (Good Mood).
The Good Mood Platform focuses on providing professional diagnosis and treatment solutions
for patients with mental and psychological diseases such as depression, anxiety, insomnia, school weariness, and bipolar disorder.
The strong alliance of the three pharmaceutical companies will fully integrate their respective field expertise, platform advantages and commercialization resources, actively carry out in-depth cooperation around Ruoxinlin, accelerate the commercialization of this variety in China, and bring good news
to patients.
China's antidepressant market has certain potential, especially with the gradual scientific understanding of depression, patients have a strong willingness to seek medical treatment, and the scale of the antidepressant market is expected to expand
rapidly.
Sullivan had predicted that in the next five years, the sample hospital market size of China's antidepressant drug industry would maintain a compound annual growth rate of 12.
7%, and would exceed 18.
4 billion yuan
in 2022.
In the face of a market of more than 10 billion, in recent years, not only multinational pharmaceutical companies, but also many local pharmaceutical companies have also actively deployed antidepressant generic drugs or innovative drugs, and the good news continues, in addition to Ruoxinlin, since this year, for example, on September 21, Fuyuan Pharmaceutical's paroxetine hydrochloride enteric-coated sustained-release tablets have been approved for production; In August, Poinsettia announced that its wholly-owned subsidiary, Guangzhou Poinsettia Pharmaceutical, had approved venlafaxine hydrochloride sustained-release capsules for marketing
.
In addition, pharmaceutical companies that have entered clinical trials include Dongguang Pharmaceutical, CSPC Pharmaceutical Group, Huahai Pharmaceutical, Tasly, Enhua Pharmaceutical, Salubris and many other pharmaceutical companies
.
With the efforts of domestic pharmaceutical companies, it is believed that more good drugs and new drugs will be launched in the future, bringing more treatment options
to domestic depression patients.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
